Association between genetic polymorphisms and osteoarthritis development. Overview of systematic reviews

Abstract Objective To identify, critically evaluate and synthesize the evidence obtained from systematic reviews on the association between genetic polymorphisms and osteoarthritis (OA) development. Methods Considering gene polymorphisms associated with OA susceptibility (risk or protection), a comprehensive search was conducted in the following databases, without date or language restrictions: MEDLINE, via Pubmed; Embase, via Elsevier; Cochrane Database of Systematic Reviews, via Wiley; Biblioteca Virtual em Saúde. Gray literature was also searched through the OpenGrey database. The AMSTAR‐2 (Assessing the Methodological Quality of Systematic Reviews) was used to assess the methodological quality of the included systematic reviews. Results We included 14 systematic reviews of case‐control studies comparing individuals with a radiographic diagnosis of all OA types and healthy controls, all submitted to the genetic examination of different polymorphisms in candidate genes. Meta‐analyses showed a protective effect against knee and hand OA associated with GDF‐5 gene (odds ratio [OR] 0.90, 95% confidence interval (CI) 0.85‐0.95), and knee OA with ESRα gene (OR 0.63, 95% CI 1.26‐1.97). SMAD3 gene was associated with knee and hip OA risk (OR 1.21. 95% CI 1.07‐1.38) and MMP‐1 gene was associated with temporomandibular OA (OR 1.58. 95% CI 1.26‐1.97). Conclusion Based on low‐quality to critically‐low‐quality systematic reviews, some gene polymorphisms seem to be associated with risk or protection for OA. Further high‐quality studies are needed to validate these hypotheses, contribute to disease understanding, and possibly help the decision‐making related to early diagnosis and treatment options for OA. PROSPERO register CRD42021234231.